^
Association details:
Biomarker:KRAS mutation
Cancer:Colorectal Cancer
Drug:FL118 (DDX5 degrader)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Sensitivity of colorectal or pancreatic cancers with high DDX5 and mutations in Kras and p53 genes to FL118 treatment.

Published date:
05/28/2020
Excerpt:
FL118 can eliminate the Kras/p53/APC triple-mutated SW620-established CRC tumors in a high percentage of mice at doses of 6 (maximum tolerated dose, MTD), 5, 4, 3, and 2 mg/kg. 
DOI:
10.1200/JCO.2020.38.15_suppl.e16102X